Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population

Objective: To evaluate the efficacy of multiparametric magnetic resonance imaging (mp-MRI) using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) definitions in detecting organ-confined prostate cancer. Methods: All patients who underwent radical prostatectomy between January 1, 20...

Full description

Saved in:
Bibliographic Details
Main Authors: Edwin Jonathan Aslim, Yan Mee Law, Puay Hoon Tan, John Carson Allen, Jr., Lionel Tim-Ee Cheng, Viswanath Anand Chidambaram, Li Yan Khor, Benjamin Yongcheng Tan, Ernest Wencong Eu, Christopher Wai Sam Cheng, John Shyi Peng Yuen, Henry Sun Sien Ho, Lui Shiong Lee
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Asian Journal of Urology
Online Access:http://www.sciencedirect.com/science/article/pii/S2214388218300390
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849471392956809216
author Edwin Jonathan Aslim
Yan Mee Law
Puay Hoon Tan
John Carson Allen, Jr.
Lionel Tim-Ee Cheng
Viswanath Anand Chidambaram
Li Yan Khor
Benjamin Yongcheng Tan
Ernest Wencong Eu
Christopher Wai Sam Cheng
John Shyi Peng Yuen
Henry Sun Sien Ho
Lui Shiong Lee
author_facet Edwin Jonathan Aslim
Yan Mee Law
Puay Hoon Tan
John Carson Allen, Jr.
Lionel Tim-Ee Cheng
Viswanath Anand Chidambaram
Li Yan Khor
Benjamin Yongcheng Tan
Ernest Wencong Eu
Christopher Wai Sam Cheng
John Shyi Peng Yuen
Henry Sun Sien Ho
Lui Shiong Lee
author_sort Edwin Jonathan Aslim
collection DOAJ
description Objective: To evaluate the efficacy of multiparametric magnetic resonance imaging (mp-MRI) using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) definitions in detecting organ-confined prostate cancer. Methods: All patients who underwent radical prostatectomy between January 1, 2014 and December 30, 2014 were identified. All underwent mp-MRI within 180 days before surgery. Those with prior pelvic irradiation or androgen deprivation therapy were excluded. Fully embedded, whole-mount histopathology was centrally reviewed and correlated with imaging for tumour location, Gleason score (GS) and stage. Results: There were 39 patients included, of which 35 (90%) had mp-MRI done post-biopsy. A total of 93 cancer foci were identified on whole-mount pathology, of which mp-MRI detected 63 (68%). Of those detected by mp-MRI, 14 were PI-RADS 3 (n = 6 for GS 6, n = 8 for GS 7, no GS ≥ 8) and 49 were PI-RADS 4–5 (n = 7 for GS 6, n = 33 for GS 7, and n = 9 for GS ≥ 8). There were 30 (32%) cancer foci missed by mp-MRI (n = 15 for GS 6, n = 13 for GS 7 and n = 2 for GS ≥ 8). A lesion classified as PI-RADS 4–5 predicted a higher grade cancer on pathology as compared to PI-RADS 3 (for GS 7 lesions, odds ratio [OR] = 3.53, 95% CI: 0.93–13.45, p = 0.064). The mp-MRI size detection limit was 20 mm2 and 100 mm2 for 50% and 75% probability of cancer, respectively. In associating with radiological and pathologic stage, the weighted Kappa value was 0.69 (p < 0.0001). The sensitivity and positive predictive values for this study were 68% (95% CI: 57%–77%) and 78% (95% CI: 67%–86%), respectively. Conclusion: In this predominantly post-biopsy cohort, mp-MRI using PI-RADSv2 reporting has a reasonably high diagnostic accuracy in detecting clinically significant prostate cancer. Keywords: Gleason score, Histopathology, Magnetic resonance imaging, Prostatectomy, Prostatic cancer
format Article
id doaj-art-db960fa8302147bd8776cc2eafafa3d8
institution Kabale University
issn 2214-3882
language English
publishDate 2019-07-01
publisher Elsevier
record_format Article
series Asian Journal of Urology
spelling doaj-art-db960fa8302147bd8776cc2eafafa3d82025-08-20T03:24:51ZengElsevierAsian Journal of Urology2214-38822019-07-016325626310.1016/j.ajur.2018.05.008Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient populationEdwin Jonathan Aslim0Yan Mee Law1Puay Hoon Tan2John Carson Allen, Jr.3Lionel Tim-Ee Cheng4Viswanath Anand Chidambaram5Li Yan Khor6Benjamin Yongcheng Tan7Ernest Wencong Eu8Christopher Wai Sam Cheng9John Shyi Peng Yuen10Henry Sun Sien Ho11Lui Shiong Lee12Department of Urology, Singapore General Hospital, SingaporeDepartment of Diagnostic Radiology, Singapore General Hospital, SingaporeDivision of Pathology, Singapore General Hospital, SingaporeCentre of Quantitative Medicine, DUKE-NUS Medical School, SingaporeDepartment of Diagnostic Radiology, Singapore General Hospital, SingaporeDepartment of Diagnostic Radiology, Singapore General Hospital, SingaporeDepartment of Anatomical Pathology, Singapore General Hospital, SingaporeDepartment of Anatomical Pathology, Singapore General Hospital, SingaporeDepartment of Urology, Singapore General Hospital, SingaporeDepartment of Urology, Singapore General Hospital, SingaporeDepartment of Urology, Singapore General Hospital, SingaporeDepartment of Urology, Singapore General Hospital, SingaporeDepartment of Urology, Singapore General Hospital, Singapore; Corresponding author.Objective: To evaluate the efficacy of multiparametric magnetic resonance imaging (mp-MRI) using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) definitions in detecting organ-confined prostate cancer. Methods: All patients who underwent radical prostatectomy between January 1, 2014 and December 30, 2014 were identified. All underwent mp-MRI within 180 days before surgery. Those with prior pelvic irradiation or androgen deprivation therapy were excluded. Fully embedded, whole-mount histopathology was centrally reviewed and correlated with imaging for tumour location, Gleason score (GS) and stage. Results: There were 39 patients included, of which 35 (90%) had mp-MRI done post-biopsy. A total of 93 cancer foci were identified on whole-mount pathology, of which mp-MRI detected 63 (68%). Of those detected by mp-MRI, 14 were PI-RADS 3 (n = 6 for GS 6, n = 8 for GS 7, no GS ≥ 8) and 49 were PI-RADS 4–5 (n = 7 for GS 6, n = 33 for GS 7, and n = 9 for GS ≥ 8). There were 30 (32%) cancer foci missed by mp-MRI (n = 15 for GS 6, n = 13 for GS 7 and n = 2 for GS ≥ 8). A lesion classified as PI-RADS 4–5 predicted a higher grade cancer on pathology as compared to PI-RADS 3 (for GS 7 lesions, odds ratio [OR] = 3.53, 95% CI: 0.93–13.45, p = 0.064). The mp-MRI size detection limit was 20 mm2 and 100 mm2 for 50% and 75% probability of cancer, respectively. In associating with radiological and pathologic stage, the weighted Kappa value was 0.69 (p < 0.0001). The sensitivity and positive predictive values for this study were 68% (95% CI: 57%–77%) and 78% (95% CI: 67%–86%), respectively. Conclusion: In this predominantly post-biopsy cohort, mp-MRI using PI-RADSv2 reporting has a reasonably high diagnostic accuracy in detecting clinically significant prostate cancer. Keywords: Gleason score, Histopathology, Magnetic resonance imaging, Prostatectomy, Prostatic cancerhttp://www.sciencedirect.com/science/article/pii/S2214388218300390
spellingShingle Edwin Jonathan Aslim
Yan Mee Law
Puay Hoon Tan
John Carson Allen, Jr.
Lionel Tim-Ee Cheng
Viswanath Anand Chidambaram
Li Yan Khor
Benjamin Yongcheng Tan
Ernest Wencong Eu
Christopher Wai Sam Cheng
John Shyi Peng Yuen
Henry Sun Sien Ho
Lui Shiong Lee
Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
Asian Journal of Urology
title Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
title_full Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
title_fullStr Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
title_full_unstemmed Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
title_short Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
title_sort multiparametric mri reporting using prostate imaging reporting and data system version 2 0 pi radsv2 retains clinical efficacy in a predominantly post biopsy patient population
url http://www.sciencedirect.com/science/article/pii/S2214388218300390
work_keys_str_mv AT edwinjonathanaslim multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT yanmeelaw multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT puayhoontan multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT johncarsonallenjr multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT lioneltimeecheng multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT viswanathanandchidambaram multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT liyankhor multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT benjaminyongchengtan multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT ernestwencongeu multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT christopherwaisamcheng multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT johnshyipengyuen multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT henrysunsienho multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation
AT luishionglee multiparametricmrireportingusingprostateimagingreportinganddatasystemversion20piradsv2retainsclinicalefficacyinapredominantlypostbiopsypatientpopulation